Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Am Heart J. 2017 Dec 27;198:108–114. doi: 10.1016/j.ahj.2017.12.016

Figure 3.

Figure 3

Mean total and hormone sensitive spending during the intervention phases of the CEE+MPA trial (median follow 5.1 years) and the CEE-alone trial (median follow-up 6.7 years). The global index spending includes coronary heart disease, invasive breast cancer, pulmonary embolism, stroke, colorectal cancer, hip fracture and, for the CEE+MPA trial, endometrial cancer.